1040199-08-3Relevant academic research and scientific papers
Synthesis and activity of tetrapeptidic HTLV-I protease inhibitors possessing different P3-cap moieties
Zhang, Meihui,Nguyen, Jeffrey-Tri,Kumada, Henri-Obadja,Kimura, Tooru,Cheng, Maosheng,Hayashi, Yoshio,Kiso, Yoshiaki
, p. 5795 - 5802 (2008/12/20)
The causative agent behind adult T-cell leukemia and tropical spastic paraparesis/HTLV-I-associated myelopathy is the human T-cell leukemia virus type 1 (HTLV-I). Tetrapeptidic HTLV-I protease inhibitors were designed on a previously reported potent inhibitor KNI-10516, with modifications at the P3-cap moieties. All the inhibitors showed high HIV-1 protease inhibitory activity (over 98% inhibition at 50 nM) and most exhibited highly potent inhibition against HTLV-I protease (IC50 values were less than 100 nM).
Truncation and non-natural amino acid substitution studies on HTLV-I protease hexapeptidic inhibitors
Nguyen, Jeffrey-Tri,Zhang, Meihui,Kumada, Henri-Obadja,Itami, Ayako,Nishiyama, Keiji,Kimura, Tooru,Cheng, Maosheng,Hayashi, Yoshio,Kiso, Yoshiaki
, p. 366 - 370 (2008/09/18)
The culprit behind adult T-cell leukemia, myelopathy/tropical paraparesis, and a plethora of inflammatory diseases is the human T-cell leukemia virus type 1 (HTLV-I). We recently unveiled a potent hexapeptidic HTLV-I protease inhibitor, KNI-10166, compose
